Trial
NCT02623920
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Arizona
Collaborators
—
Condition
Diffuse Large B Cell Lymphoma
Intervention
Brentuximab
Why stopped
Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close study prior to enrollment of any patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-19